IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Lazard Asset Management LLC

Lazard Asset Management LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 450.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,642 shares of the company’s stock after purchasing an additional 30,804 shares during the quarter. Lazard Asset Management LLC’s holdings in IDEXX Laboratories were worth $20,323,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Valley National Advisers Inc. raised its holdings in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares during the period. Riverview Trust Co purchased a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Crewe Advisors LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter worth approximately $26,000. DSM Capital Partners LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $33,000. Finally, Private Wealth Management Group LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.2 %

Shares of NASDAQ:IDXX opened at $469.71 on Monday. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The firm’s 50 day moving average price is $493.61 and its 200 day moving average price is $516.90. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The stock has a market cap of $38.79 billion, a price-to-earnings ratio of 45.47, a price-to-earnings-growth ratio of 3.84 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now owns 161 shares in the company, valued at $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.11% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on IDXX shares. Morgan Stanley cut their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday. They set a “buy” rating and a $580.00 price target on the stock. Finally, William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $585.89.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.